Specificity of Cortical Area and Thickness As Biomarkers for Comorbid Internalizing and Externalizing Mental Disorders in Pre-Adolescence
Nanyu Kuang,Zhaowen Liu,Gechang Yu,Kai Zhang,Xinran Wu,Ben Becker,Huaxin Fan,Jiajia Zhao,Jujiao Kang,Guiying Dong,Xingming Zhao,Jianfeng Feng,Barbara J. Sahakian,Trevor W. Robbins,Gunter Schumann,Lena Palaniyappan,Jie Zhang
DOI: https://doi.org/10.1101/2022.04.24.22273790
2022-01-01
MedRxiv
Abstract:Background Comorbidity is the rule rather than the exception for childhood and adolescent onset mental disorders, but we cannot predict its occurrence and do not know the neural mechanisms underlying comorbidity. We investigate if the effects of comorbid internalizing and externalizing disorders on anatomical changes represent a simple aggregate of the effects on each disorder, and if comorbidity-related cortical surface changes relate to a distinct genetic underpinning.Methods We studied the cortical surface area (SA) and thickness (CT) of 11,878 preadolescents (9-10 years) from the Adolescent Brain and Cognitive Development Study. Linear mixed models were implemented in comparative and association analyses among internalizing (Dysthymia, Major Depressive Disorder, Disruptive Mood Dysregulation Disorder, Agoraphobia, Panic Disorder, Specific Phobia, Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder, Post-Traumatic Stress Disorder), externalizing diagnostic groups (Attention-Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct disorder) a group with comorbidity of the two and a healthy control group. Genome-wide association analysis and cell type specificity analysis were performed on 4,716 unrelated European participants from this cohort.Results Reduced cortical surface area but increased thickness occurs across patient groups when compared to controls. Children with comorbid internalizing and externalizing disorders had more pronounced areal reduction than those without comorbidity, indicating an additive burden. In contrast, cortical thickness had a non-linear effect with comorbidity: the comorbid group had no significant CT changes, while those patient groups without comorbidity had significant thickness increases. Distinct biological pathways were implicated for regional SA and CT changes. Specifically, CT changes were associated with immune-related processes implicating microglia, while SA-related changes related mainly to excitatory neurons.Conclusions The emergence of comorbidity across distinct clusters of psychopathology is unlikely to be a simple additive neurobiological effect. Distinct risk-adaptation processes, with unique genetic and cell-specific factors may underlie SA and CT changes. Children with highest risk but lowest resilience, both captured in their developmental morphometry, develop a comorbid illness pattern.### Competing Interest StatementThe authors have declared no competing interest.### Funding StatementAcknowledgments JZ was supported by Shanghai Municipal Science and Technology Major Project (No.2018SHZDZX01) and ZJLab and NSFC 61973086. JF was supported by the 111 Project (No. B18015), the key project of Shanghai Science and Technology (No. 16JC1420402), National Key R&D Program of China (No. 2018YFC1312900), National Natural Science Foundation of China (NSFC 91630314). LP acknowledges salary support from the Tanna Schulich Chair of Neuroscience and Mental Health. Kai Zhang is Sponsored by Shanghai Pujiang Program.### Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLP reports personal fees from Janssen Canada, Otsuka Canada, SPMM Course Limited, UK, Canadian Psychiatric Association; book royalties from Oxford University Press; investigator-initiated educational grants from Janssen Canada, Sunovion and Otsuka Canada outside the submitted work. All other authors report no biomedical financial interests or potential conflicts of interest. None of the above-listed companies or funding agencies have had any influence on the content of this article.